Anticancer agents that selectively kill tumor cells and spare normal tissues are urgently needed. Here, we engineered a cell-permeable peptidomimetic, shepherdin, modeled on the binding interface between the molecular chaperone Hsp90 and the antiapoptotic and mitotic regulator, survivin. Shepherdin makes extensive contacts with the ATP pocket of Hsp90, destabilizes its client proteins, and induces massive death of tumor cells by apoptotic and nonapoptotic mechanisms. Conversely, shepherdin does not reduce the viability of normal cells, and does not affect colony formation of purified hematopoietic progenitors. Systemic administration of shepherdin in vivo is well tolerated, and inhibits human tumor growth in mice without toxicity. Shepherdin could provide a potent and selective anticancer agent in humans.
Introduction
target the survivin pathway in cancer are being vigorously pursued, and clinical testing of survivin antisense oligonucleotides Despite a better understanding of the biology of tumor cells has recently begun. A nodal point for the multiple functions of ( Vogelstein and Kinzler, 2004) , the treatment of most cancers survivin in tumor cells is its association with heat shock protein has not significantly changed for the past three decades, and 90 (Hsp90), which is required to preserve survivin stability, drugs that do not discriminate between tumor cells and normal in vivo (Fortugno et al., 2003) . Hsp90 is an ATPase-directed tissues remain mainstays of anticancer therapy. Disabling an molecular chaperone that oversees protein folding quality conessential oncogenic pathway has produced encouraging retrol during the cellular stress response, and whose repertoire sults in the management of certain malignancies (O'Dwyer and of client proteins is typically restricted to signaling molecules Druker, 2000; Paez et al., 2004) . However, this type of "tarinvolved in cell proliferation and cell survival (Young et al. , geted" therapy may not be immediately applicable to most 2001). This is thought to play a key role in cancer, where Hsp90 solid tumors, in which the accumulation of numerous molecular is commonly upregulated, and its stress response recognition abnormalities (Vogelstein and Kinzler, 2004) and genomic instamay help promote tumor cell adaptation in face of unfavorable bility (Sieber et al., 2003) may elude the identification of a sinenvironments (Isaacs et al., 2003) . Conversely, this pathway gle, driving oncogene. Conversely, pathways that intersect has created a viable therapeutic opportunity (Sausville et al., multiple essential functions of tumor cells may provide broader 2003) , and molecular targeting of Hsp90 ATPase activity by the therapeutic prospects. A candidate for such an approach is class of ansamycin antibiotics prototypically exemplified by survivin, an essential regulator of cell proliferation, differentiaGeldanamycin (GA) (Neckers and Ivy, 2003) has shown promistion, and apoptosis that is sharply overexpressed in cancer ing anticancer activity for disabling multiple signaling networks versus normal tissues, and frequently linked to unfavorable disrequired for tumor cell maintenance (Basso et al., 2002) . ease outcome . Because of its role at a crossroad Here, we used structure-based mimicry to disrupt the surof multiple cellular functions (Okada and Mak, 2004) , and the vivin-Hsp90 interaction, and test its suitability as a novel drug likelihood that survivin antagonists may have selective antitumor efficacy in vivo , drug discovery efforts to target in cancer.
S I G N I F I C A N C E
It has long been appreciated that tumor cells are "stressed" cells capable of coping with unfavorable environments via a generalized upregulation of their stress response machinery. This is largely centered on the expression and function of the molecular chaperone Hsp90, which has provided an attractive target for therapeutic intervention in cancer. Here, we report the structure-based design and characterization of shepherdin, a novel peptidomimetic antagonist of the complex between Hsp90 and survivin, another key regulator of tumor cell viability. For its potent and broad antitumor activity, selectivity of action in tumor cells versus normal tissues, and inhibition of tumor growth in vivo without toxicity, shepherdin may offer a promising approach for rational cancer therapy.
cellular context, we reconstituted this interaction in reticulocyte extracts, which have been used before to assemble functional Hsp90 complexes (Morishima et al., 2000) . Recombinant survivin added to untreated reticulocyte extracts formed a complex with endogenous Hsp90, as detected by coimmunoprecipitation and Western blotting ( Figure 1B ). In contrast, a control IgG did not immunoprecipitate survivin from reticulocyte extracts ( Figure 1B ). Preincubation of reticulocyte extracts with shepherdin completely inhibited the association of recombinant survivin with Hsp90, whereas a scrambled peptide had minimal effect ( Figure 1B) . Next, we asked whether shepherdin interfered with ATP binding to Hsp90 (Marcu et al., 2000) . Addition of a scrambled peptide to recombinant N-domain of Hsp90 (residues 1-272) did not affect binding to ATP-sepharose, as shown by affinity chromatography ( Figure 1C ). In contrast, shepherdin blocked the interaction between N-Hsp90 and immobilized ATP, which was also fully competed out by addition of soluble ATP ( Figure 1C ). To map the requisites of shepherdin binding to Hsp90, we generated mutant peptides with single amino acid substitutions. Mutagenesis of H80, S81, S82, G83, and C84 abolished shepherdin binding to Hsp90, whereas substitution of K79, A85, F86, or L87 had no effect ( Figure 1D ). In the survivin crystal structure, amino acids H80-G83 form a flexible loop connecting the fourth and fifth α helices of the baculovirus IAP repeat, and H80 contributes to a A: Affinity chromatography. S100 Raji cell extracts were fractionated over surface-exposed "basic patch" (Verdecia et al., 2000) . herdin and G83-S84 in shepherdin-RV, and overall β-hairpin geometry ( Figure 2A ). The most populated conformation of shepherdin-RV shows a higher degree of compactness, with the aromatic ring of F80 packing on the turn region ( Figure 2A ).
Results
The representative β-hairpin conformations of shepherdins were subjected to multiple docking experiments on Hsp90 Identification of shepherdin using the AutoDock program package (Morris et al., 1998) . In Using synthetic peptidyl mimicry, we recently identified a surall cases, the peptides were predicted to dock into the ATP vivin sequence K79-K90, which blocks the interaction between binding site of Hsp90 ( Figures 2B and 2C ). The geometry of survivin and Hsp90, in vitro (Fortugno et al., 2003) . By surface the final complex is highly correlated with that of the complex plasmon resonance, the survivin K79-K90 peptide bound between Hsp90 and GA (Stebbins et al., 1997) , with the turn Hsp90 with high affinity (K D ± SEM = 8.38 x 10 −8 ± 3.5 −9 M) region of the peptides closely tracing the ansa ring backbone at increasing ligand concentrations (0.1-10 M). Conversely, a of GA ( Figures 2D and 2E ). Shepherdin and shepherdin-RV mutant C84/A peptide (see below) did not bind Hsp90, and make 13 and 18 predicted hydrogen bonds with the ATP exhibited a 10-fold increased off-rate as compared with the pocket of Hsp90, respectively, involving the side chains of H80, wild-type sequence, as shown by surface plasmon resonance. S81, S82, the carbonyl group of G83, and the side chains of To narrow the minimal interacting region in K79-K90, we tested K87 and C82 (shepherdin-RV). Except for D93, the complevariant peptides, and found that the sequence I74-L87 rementary residues of Hsp90 predicted to make contact with tained the ability to bind Hsp90 in vivo with its associated shepherdin and/or shepherdin-RV largely overlap with amino chaperone Hsp70, but not Hsp27, by affinity chromatography acids implicated in GA binding (Stebbins et al., 1997) , including of B lymphoma Raji cell extracts ( Figure 1A) . Therefore, the S113, which has been recently shown to contribute to stepwise minimal survivin sequence K79-L87 was named shepherdin for accessibility of the ATP pocket of Hsp90 to GA (Lee et al., its binding to the "shepherding" chaperone Hsp90. To test 2004). Shepherdin and shepherdin-RV are predicted to assume more extended conformations than GA in the Hsp90 pocket whether shepherdin disrupted the survivin-Hsp90 complex in a ( Figures 2D and 2E ), and bury a solvent accessible surface of Next, we compared the direct binding of shepherdin to recombinant N or C domain of Hsp90. Shepherdin associated with 498 and 546 Å 2 , respectively, as opposed to 402 Å 2 buried by GA.
the N domain Hsp90 in a concentration-dependent and saturable manner ( Figure 3C ). In contrast, no specific binding of To check these structural predictions, and validate experimentally that shepherdin engaged Hsp90 differently from GA, shepherdin to the C domain of Hsp90 was demonstrated, as compared with scrambled peptide ( Figure 3C ). we introduced targeted mutations in the ATP pocket of Hsp90, and tested their effect on shepherdin binding. Individual substitution of N51, S52, D102, or S113 in the N domain of Hsp90
Intracellular delivery of shepherdin induces reduced binding to shepherdin by 20%-60%, whereas mutatumor cell death genesis of "GA-specific" D93 had no effect, and a scrambled Cell-permeable variants of shepherdin were generated by fuspeptide did not bind wild-type or mutant Hsp90 ( Figure 2F ).
ing the peptide N termini to either helix III of the Antennapedia homeodomain protein (shepherdin
Atp
) (Kabouridis, 2003) or the HIV-Tat sequence (shepherdin Tat   ) . Both cell-permeable shepMolecular requirements of shepherdin-Hsp90 recognition We next tested the interaction of shepherdin with individual doherdin variants as well as their control scrambled sequences rapidly (<1 hr) accumulated inside 100% of cervical carcinoma mains of Hsp90, and we first analyzed the middle domain (M) for its role in client protein loading (Meyer et al., 2003) . Blind HeLa cells ( Figure 4A ), and showed identical efficiency of intracellular penetration in single cell fluorescence analysis ( cumulation decreasing sharply at lower peptide concentrations peptides had no effect on tumor cell viability ( Figures 4C-4F and not shown). (not shown). Next, we looked at the effect of intracellular delivery of shepherdin, and for all subsequent studies shepherdin Atp was used unless otherwise specified. Treatment of HeLa cells Shepherdin inhibits Hsp90 chaperone function with increasing concentrations of shepherdin resulted in cata-A potential model to explain these findings is that shepherdin strophic loss of cell viability, with the entire cell population engagement of the ATP pocket of Hsp90 (Figures 2B-2F) deexhibiting hypodiploid DNA content, as shown by propidium stabilizes its client proteins, resulting in the acute breakdown iodide staining and flow cytometry ( Figure 4C ). In contrast, a of multiple cell survival pathways (Isaacs et al., 2003) , including cell-permeable scrambled peptide, or shepherdin peptides survivin (Fortugno et al., 2003) . To test this prediction, we exwithout cell penetrating sequences, were without effect (Figure amined the levels of Hsp90 client proteins after intracellular loading of shepherdin or scrambled peptide. Prostate carci-4C and not shown). In clonogenic assays, cell-permeable shepherdin, but not a scrambled peptide, completely abolished noma PC3 cells treated with shepherdin exhibited loss of multiple Hsp90 client proteins, including survivin, Akt, CDK-4, and colony formation in soft agar (not shown). To identify the mechanism(s) by which shepherdin killed tumor cells, we examined CDK-6, as shown by Western blotting ( Figure 5A and not shown). In contrast, shepherdin did not affect the levels of activation of nonapoptotic and apoptotic cell death pathways.
Treatment of HeLa cells with shepherdin
Atp or shepherdin Tat reHsp90, Hsp70, or PCNA, and a cell-permeable scrambled peptide did not modulate chaperone or client protein expression sulted in rapid loss of plasma membrane integrity, with the entire cell population becoming Trypan blue-positive by 3-6 hr ( Figure 5A ). We also tested the effect of shepherdin on telomerase activity, which requires Hsp90 (Holt et al., 1999) . TRAP after peptide addition ( Figure 4D ). Within the same time frame, shepherdin also induced activation of mitochondrial apoptosis, analysis of Hsp90 immunoprecipitates from PC3 cells revealed that shepherdin treatment almost completely abrogated the with release of mitochondrial cytochrome c in the cytosol (Figure 4E) . This was accompanied by typical hallmarks of apoptoenzyme's catalytic activity, as compared with untreated or scrambled peptide-treated cells ( Figure 5B ). Because of the sis, including appearance of annexin V-labeled cells, and expression of caspase activity, as shown by multiparametric flow structural and functional similarities between shepherdin and small molecule Hsp90 antagonist(s), e.g., GA, we compared cytometry ( Figure 4F ). Preincubation of HeLa cells with a caspase inhibitor, ZVAD-fmk (20 M), only partially attenuated cell the antitumor efficacy of shepherdin with that of 17-AAG, a derivative of GA currently in the clinic (Sausville et al., 2003) . A death induced by shepherdin (64.6 ± 10% cell death versus 82.6 ± 4.4% at 125 M shepherdin, n = 3). Identical results 5 hr shepherdin treatment of various tumor cell lines resulted in dose-dependent and complete cell killing ( Figure 5C ). In were obtained with cell-permeable shepherdin-RV, which also induced loss of plasma membrane integrity and caspase acticontrast, 17-AAG had no effect on tumor cell viability within this time frame ( Figure 5C ). With a prolonged incubation up vation in tumor cells (not shown). Conversely, intracellular accumulation of cell-permeable native or retro-inverso scrambled to 24 hr, the highest concentration of 17-AAG tested (10 M) produced w50% cell death ( Figure 5C ), thus confirming its anin p53 +/+ or p53 −/− HCT116 cells ( Figure 6B ). Lastly, overexpression of Bcl-2 in HeLa cells using a replication-defective titumor activity (Basso et al., 2002) .
adenovirus effectively counteracted apoptosis induced by staurosporine, but did not reduce shepherdin-mediated cell Requirements of shepherdin-induced tumor cell killing Tumors with low proliferative index that have lost the p53 tumor killing ( Figure 6C ). In all experiments, a cell permeable scrambled peptide was without effect (Figures 6A-6C ). suppressor gene, or that upregulate antiapoptotic mechanisms, notably Bcl-2, are likely to become resistant to conventional anticancer therapy (Johnstone et al., 2002) , and to evade Selectivity of shepherdin antitumor activity One of the pivotal objectives of "targeted" cancer therapy is to checkpoint-based "targeted" therapy (Vassilev et al., 2004) . Therefore, it was of interest to test whether these conditions selectively eliminate tumor cells while sparing normal tissues. Therefore, we asked whether shepherdin was a selective antiaffected shepherdin-mediated antitumor activity. Treatment of a panel of tumor cell lines with shepherdin resulted in comparacancer agent, discriminating between normal and tumor cells. When added to prostate carcinoma (PC3, DU145) or HeLa ble levels of cell killing whether cells were actively proliferating or made quiescent by prior serum starvation ( Figure 6A ). Seccells, shepherdin caused concentration-dependent and complete loss of cell viability ( Figure 7A ), consistent with the data ondly, shepherdin was equally effective at inducing caspasedependent apoptosis and loss of plasma membrane integrity presented above. In contrast, identical concentrations of shep-ern blotting ( Figure 7D ), and in agreement with the data presented above ( Figure 1A ). In contrast, chromatography of normal peripheral blood mononuclear cell (PBMC) extracts over shepherdin-sepharose did not yield immunoreactive bands, indicating that shepherdin has little, if any, affinity for Hsp90 in normal cells, and no independent recognition for Hsp70 ( Figure  7D ). In addition, silver staining analysis of shepherdin-bound material eluted from Raji cell extracts revealed the presence of only two main bands of w70 and w90 kDa, demonstrating that shepherdin specificity in vivo is highly restricted ( Figure 7E ).
Antitumor activity of shepherdin in vivo
To test the efficacy of shepherdin in human cancer models, we first grew prostate carcinoma PC3 cells as superficial tumors in immunocompromised mice, and started treatment when tumors became palpable (w35-70 mm
3
). For these studies, shepherdin-RV was used. Control animals given saline exhibited progressive tumor growth during an 11-day interval ( Figure  8A ). Conversely, administration of shepherdin-RV (50 mg/kg, i.p., daily) nearly completely ablated tumor growth ( Figure 8A ). Within 1 hr of injection, shepherdin-RV accumulated in the tumor mass, by fluorescence microscopy, whereas tumors of saline-injected animals had only background fluorescence ( Figure  8B ). Secondly, we tested shepherdin-RV in a breast cancer xenograft model that employs MCF-7 cells adapted in vivo. Injec- at the end of treatment revealed no alterations in cell counts or blood chemistry in shepherdin-versus saline-treated animals (Supplemental Table S2 ). In addition, histologic examination of lung, spleen, and liver was equally unremarkable in the saline herdin did not reduce the viability of normal human fibroblasts or shepherdin group, and extramedullary hematopoiesis in the of three different tissue origins ( Figure 7A ), and a cell-permespleen red pulp occurred with comparable frequency in control able scrambled peptide had no effect on normal or tumor cells or shepherdin-treated mice ( Figure 8D ). To test whether shep-( Figure 7A ). Similarly, shepherdin did not reduce the viability of herdin caused loss of Hsp90 client proteins in the context of nontransformed mouse embryonic fibroblasts (MEF), whereas the tumor mass in vivo, we analyzed MCF-7 tumors recovered it efficiently killed JC mouse mammary carcinoma cells ( Figure 8E ). Similar results were obtained by Western blotcient to ablate tumor cell viability (see above) did not signifiting analysis of tumor cell extracts, with considerable reduction cantly reduce colony formation along the erythroid or myeloid of survivin and Akt levels after shepherdin treatment, as comlineage, as compared with scrambled peptide-treated cultures pared with the saline group ( Figure 8F ). (Figure 7C ).
Hsp90 has been reported to bind ATP pocket inhibitors, i.e., Discussion 17-AAG, with a w100-fold higher affinity in tumor cells as opposed to normal tissues, and this high-affinity conformation
In this study, we used structure-based rational prediction to may enhance the tumor selectivity of Hsp90 antagonists (Kaidentify and characterize shepherdin, a novel anticancer peptimal et al., 2003). To test whether shepherdin also differentially domimetic modeled on the survivin-Hsp90 binding interface bound Hsp90 from normal or tumor cells, we carried out affinity (Fortugno et al., 2003) . Shepherdin engages the ATP pocket of chromatography experiments. Fractionation of B lymphoma Hsp90 with unique binding characteristics, destabilizes surRaji cell extracts over shepherdin-sepharose resulted in the isolation of Hsp90, and coelution of Hsp70, as shown by Westvivin plus several additional client proteins, and causes mas- Figure 1C ), and analyzed after 12 hr by MTT. Bcl-2 cytoprotection from staurosporine (STS)-induced apoptosis (1 M) was used as a control.
sive killing of tumor cells by apoptotic and nonapoptotic mech-2003) , and reflect the efficiency of intracellular penetration rather than the affinity of the mimetic for the target. The ability anisms. Shepherdin is selective in its antitumor activity, and does not affect the viability of normal cells or tissues, including of shepherdin to trigger both apoptotic and nonapoptotic cell death may explain its broad antitumor activity, which indistinhuman hematopoietic progenitors. When administered in vivo, shepherdin is safe and well tolerated, and inhibits growth of guishably affected tumor cell types of different derivations, regardless of their proliferative condition (Swanton, 2004) , p53 different tumor cell types without systemic or organ toxicity. Taken together, these features may make shepherdin an attracstatus (Vogelstein et al., 2000) , or overexpression of potent survival signals, e.g., Bcl-2 (Johnstone et al., 2002) , all conditions tive lead prodrug for "targeted" cancer therapy.
Although initially designed as a high-affinity (K D w80 nM) that typically compromise the efficacy of conventional or "targeted" anticancer therapy (Vassilev et al., 2004) . In addiinhibitor of the survivin-Hsp90 interaction, the data presented here suggest that shepherdin may function as a more global tion, shepherdin kills tumor cells far more rapidly and more potently than other Hsp90 antagonists currently in the clinic, e.g., antagonist of Hsp90 chaperone activity. This conclusion is based on the structure-function analysis of shepherdin, and in 17-AAG (Sausville et al., 2003) . As demonstrated by affinity chromatography, this higher antitumor efficacy of shepherdin particular its ability to expansively engage the chaperone ATP pocket, compete for the Hsp90-ATP complex, and destabilize can not be explained with nonspecific recognition of multiple cellular proteins, and does not involve an independent specificmultiple Hsp90 client proteins in addition to survivin, in vivo. Because of these features, shepherdin appears ideally suited ity for Hsp70, a regulator of mitochondrial apoptosis and caspase-independent cell death (Beere, 2004) . Conversely, it to interfere with the periodicity of Hsp90 ATPase cycles, by directly preventing ATP binding (Stebbins et al., 1997) , and/or seems plausible that by virtue of its unique binding interface with Hsp90, shepherdin may disrupt additional, and potentially by competing with cochaperone recruitment, especially that of p50 cdc37 , which is required for ATPase activity and shares overas yet unrecognized, cell survival functions of the chaperone that are not efficiently compromised by GA or 17-AAG. lapping binding contacts with shepherdin . In this context, the simultaneous destabilization of survivin levels When tested as an anticancer agent in tumor models, shepherdin was selective and well-tolerated, sparing normal cells, , combined with the acute collapse of Hsp90 function (Isaacs et al., 2003) , would be expected to cause a preserving colony-forming ability of purified human hematopoietic progenitors, and causing no organ or systemic toxicity afgeneral breakdown of multiple cell proliferation and cell survival pathways in tumor cells, suitable for therapeutic exploitation ter prolonged administration in vivo. This desirable selectivity may involve the differential overexpression of survivin and (Neckers and Ivy, 2003) . Consistent with this model, a brief exposure of disparate tuHsp90 in tumors as opposed to normal tissues Isaacs et al., 2003) , as well as qualitative changes in Hsp90, mor cell lines to cell-permeable variants of shepherdin resulted in massive and complete cell killing via activation of nonapowhich exhibits a w100-fold higher affinity for binding ATP pocket antagonists in tumor versus normal cells. Previously ptotic and apoptotic mechanisms, the latter involving mitochondrial dysfunction, i.e., permeability transition. The concendemonstrated for 17-AAG (Kamal et al., 2003) , a similar paradigm can be extended to shepherdin, which bound avidly to trations of shepherdin needed to achieve complete tumor cell killing (IC 50 w25-75 M, depending on the cell penetrating seHsp90 in lymphoma cells, but not at all in normal human mononuclear cells. quence), are in line with those of previous studies using cellpermeable carrier sequences (Chen et al., 1999; Sawada et al., In summary, shepherdin has the molecular features of both + hematopoietic progenitor cells were incubated with shepherdin Atp or scrambled peptide for 2.5 hr and plated in semisolid medium with cytokines, and colonies were scored after 10-12 days. CFU-E, colony-forming unit, erythroid; BFU-E, burst-forming unit, erythroid; CFU-GM, colony-forming unit, granulocyte-macrophage; CFU-M, colony-forming unit, macrophage; CFU-GEMM, colonyforming unit, granulocyte, erythroid, macrophage. Data are the mean ± SD of 2 individual replicates. D: Affinity chromatography. Extracts from B lymphoma Raji cells or freshly isolated normal PBMC were fractionated over shepherdin-sepharose, and eluted material was analyzed by Western blotting. WCE, whole cell extracts. E: Silver staining. The experimental conditions are the same as in D, except that fractions eluted from Raji cell extracts over shepherdinsepharose were analyzed by silver staining. WCE, whole cell extracts. 
Experimental procedures
1999) (underlined) and fused at the peptide N termini was also used as follows: biotin-X-YGRKKRRQRRRKHSSGCAFL-CONH 2 (shepherdin Tat   ) . A Cells and cell cultures The following human normal or tumor cell lines were obtained from the control scrambled peptide using the HIV Tat protein (underlined) was also synthesized as: biotin-X-YGRKKRRQRRRSKLACFSHG-CONH 2 . X = EAHX, American Type Culture Collection (ATCC), and maintained in culture as recommended by the supplier: foreskin fibroblasts HFF, gingival fibroblasts hexanoic acid spacer. Mutant peptides of the shepherdin sequence carrying single amino acid substitutions at each position were also synthesized. Ev-CONH 2 . X = EAHX, hexanoic acid spacer. Individual recombinant Hsp90 domains (N domain, residues 1-272; M domain, residues 273-617; C doery residue was mutated to Ala except Ala85, which was changed to Gly. A main, residues 629-732) cloned in pGex-4T3 (Pharmacia Biotech) and cell-permeable "retro-inverso" (Pescarolo et al., 2001) shepherdin peptide pFLAG-CMV 6c (Sigma) were expressed in BL-21 E. coli and purified from (shepherdin-RV) fused to the Antennapedia sequence was synthesized the GST frame by overnight thrombin (1 U/ml) cleavage, as described (Forusing Fmoc chemistry and solid phase purification using all D amino acids tugno et al., 2003) . in the reverse orientation (Herve et al., 1997; Hong et al., 1999) , and with Val substituting Ile in the Antennapedia sequence (Brugidou et al., 1995) 8 Raji cells were collected, lysates were immunoprecipitated with a rabbit polyclonal antibody to Hsp90 washed once in ice-cold TBS, suspended in 4 ml of lysis buffer (25 mM (Santa Cruz) precoupled to 8 l of a 50% slurry of protein-G-agarose beads Hepes [pH 7.4], 100 mM KCl, 2 mM EGTA, 1% Triton-X100, 50 mM NaF, 10 for 1 hr at 4°C. After washes, the immune complexes were analyzed for mM Na 3 VO 4 , plus protease inhibitors), and passed trough a 26-gauge telomerase activity by telomeric repeat amplification protocol (TRAP) assay needle three times. An S100 fraction was obtained by centrifugation at using the TRAPeze kit (Intergen, UK). Each reaction product was amplified 100,000 × g for 30 min at 4°C. The cleared lysate (10 mg/ml) was loaded in the presence of a 36 bp internal TRAP assay standard (ITAS). TSR8 (R8) on the survivin peptide resin or an empty resin as control. After washes in quantitation standard (which serves as a standard to estimate the amount lysis buffer, proteins were eluted in 2% SDS, 20 mM Tris (pH 7.5). Samples of product extended by telomerase in a given extract) was included for each were separated onto a 12% SDS gel, and analyzed by Western blotting.
set of TRAP assay. For peptide competition of Hsp90-ATP interaction (Marcu et al., 2000) , three g of recombinant Hsp90 N domain (1-272) was incubated with 10 mM CD34 + hematopoietic stem cell colony formation assay ATP, shepherdin, or scrambled peptide (150 M) in 200 l of molybdate
The experiments were carried out as described previously (Pisarev et al., buffer containing 10 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 , 10 mM NAMoO 4 , 2003). Briefly, human CD34 + hematopoietic progenitor cells were isolated and 0.2% Tween 20 for 2 hr at 4°C under constant agitation. Samples were from buffy coats of normal healthy volunteers using a magnetic bead sepafurther incubated with 50 l of γ-phosphate-linked ATP-sepharose (Boca ration system (Miltenyi Biotec, Auburn, CA), and incubated with increasing Scientific) for 2 hr at 4°C and washed, and bound material was eluted in concentrations of shepherdin Atp or scrambled peptide for 2.5 hr at 37°C. 5% SDS and analyzed by Western blotting. In other experiments, Raji or CD34 + cells were plated in duplicates into 6-well plates (5,000 cells per PBMC cells were lysed in 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% well) in 2.5 ml of methylcellulose medium MethoCult GF H4434 (Stem Cell deoxycholate, 1% Triton X-100 plus protease inhibitors, and extracts (200 Technologies, Vancouver, Canada), containing cytokines supporting growth g) were applied to shepherdin-sepharose (5 mg/ml of resin, 0.5 ml) and of myeloid and erythroid colonies. Colonies were scored on day 10-12. incubated for 1 hr at 4°C. Bound material was eluted with glycine (pH 2.5) and analyzed by Western blotting or silver staining. A functional survivinXenograft tumor models Hsp90 complex was reconstituted in a cellular context using rabbit reticuloAll experiments involving animals were approved by an Institutional Animal cyte extracts (Morishima et al., 2000) . Aliquots of reticulocyte extracts (35 Care and Use Committee. For in vivo adaptation, 2.5 × 10 6 MCF-7 cells l in a total volume of 70 l) were left untreated or incubated with shepwere injected into the flanks of CB-17 SCID/beige mice (Taconics), and herdin or control peptide (150 M) for 3 hr at 22°C, mixed with recombinant grown as solid tumors for 2 weeks. Tumors were excised and minced under survivin (1 g) for 1 hr at 22°C, and immunoprecipitated with control IgG or sterile conditions, and the derived cell suspension was plated in complete an antibody to Hsp90. The immune complexes were precipitated with progrowth media, maintained in a 5% CO 2 humidified incubator at 37°C, and tein G slurry, washed, and probed with antibodies to Hsp90 or survivin by used for further xenograft tumor formation without estrogen supplementaWestern blotting.
tion. PC3 or in vivo adapted MCF-7 cells (2.5 × 10
6
) were injected into the flanks of CB17 SCID/beige mice, and allowed to form palpable solid tumors Protein binding studies for 6-7 days. When tumors reached w35-70 mm 3 in volume, animals were Mutagenesis of the Hsp90 N domain was carried out by PCR, and individual randomized in 2 groups (4/6 animals/group for PC3 xenografts, and 6 aniAla substitutions of N51, S52, D93, D102, N106, S113, and F138 were conmals/group for in vivo adapted MCF-7 xenografts), and administered saline firmed by DNA sequencing. Wild-type or mutant Hsp90 constructs were or shepherdin-RV at 50 mg/kg/daily for 11 consecutive days as i.p. injecexpressed as recombinant fusion proteins in BL-21 E. coli, and the GST tions (200 l/injection). In a second MCF-7 experiment, animals were frame was released by overnight thrombin cleavage (Fortugno et al., 2003) . treated with saline or shepherdin (50 mg/kg/daily i.p.) for 23 consecutive Shepherdin or scrambled peptide (100 g/ml) was immobilized on plastic days from inoculation. In all experiments, tumor measurements were taken microtiter plates, incubated with recombinant Hsp90 (1 g/ml) or equal condaily with a caliper, and tumor volume was calculated according to the forcentrations of N domain Hsp90 mutants (5 g/ml), and further mixed with mula 1/2 (length [mm]) × (width [mm])
2
. an antibody to Hsp90 (1 g/ml). Alternatively, shepherdin or scrambled peptide (0.03-1 mg/ml) was immobilized on plastic microtiter plates, and further Toxicity profile incubated with 1 g/ml of recombinant N-or C-domain of Hsp90 for 1 hr Animals carrying PC3 xenograft tumors were injected i.p. with saline or at 37°C. In all experiments, wells were washed 10 times, and binding of the shepherdin-RV, and sacrificed after 1 hr. The tumors were excised and primary antibody was revealed by addition of biotin-conjugated rabbit antisnap-frozen, and tissue sections were incubated with streptavidin-conjumouse IgG for 1 hr at 37°C, followed by streptavidine-alkaline phosphatase gated PE followed by fluorescence microscopy. Blood samples from aniand determination of absorbance at A 405 using p-nitrophenyl phosphate mals carrying MCF-7 xenograft tumors and treated with saline or shep-(Zymed Laboratories, CA) as substrate (Fortugno et al., 2003 ). An antibody herdin-RV were obtained at the end of treatment (day 11, experiment 1). specific for the Hsp90 N domain was purchased from Santa Cruz. A C Total cell blood counts were performed on a Heska Veterinary Hematology domain-specific antibody was from BD Transduction.
System. Blood chemistry parameters were determined using the Abaxis VetScan Comprehensive Diagnostic Profile. For histologic analysis, liver, Cell death assays and analysis of Hsp90 function Cell viability of various cell lines treated with cell-permeable shepherdin, spleen, and lungs were removed from saline-or shepherdin-treated animals carrying MCF-7 xenograft tumors at the end of treatment (day 11, experishepherdin-RV, their control scrambled peptides, or 17-AAG (Calbiochem) was determined by an MTT assay (Sigma, MO) using 200,000 cells/ml (50 ment 1). Organs were fixed in formalin and paraffin-embedded, and tissue sections were stained with hematoxylin/eosin and analyzed by light microl), or, alternatively, by Trypan blue exclusion. In some experiments, HeLa cells were transduced with an adenovirus encoding Bcl-2 at multiplicity of scopy. Alternatively, MCF-7 breast cancer xenograft tumors were excised at the end of saline or shepherdin treatment (day 23, experiment 2), formainfection of 50, treated with increasing concentrations of cell-permeable shepherdin Atp or control cell-permeable scrambled peptide, and analyzed lin-fixed, embedded in paraffin, and processed for immunohistochemistry with antibodies against survivin or Akt, according to published protocols by MTT after 12 hr. For determination of apoptosis, peptide-treated cultures were simultaneously analyzed for caspase activity and propidium iodide (PI) (Dohi et al., 2004) . In all experiments, a nonbinding IgG was substituted as a primary antibody, and gave no immunoreactivity. In other experiments, staining using CaspaTag (Intergen), or, alternatively, for Annexin V labeling
